News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Paolo Tarantino: Cure is a word we rarely use in metastatic breast cancer
Paolo Tarantino/X
May 13, 2025, 22:39

Paolo Tarantino: Cure is a word we rarely use in metastatic breast cancer

Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn:

“Cure. A word we rarely use in patients with metastatic breast cancer, for good reasons. Yet, 25 years of targeting HER2 taught us that some HER2+ breast cancers, even when spread, can respond so well to anticancer treatment that never reappear.

Glad to contribute with an interview to this excellent article on the topic.”

Paolo Tarantino

More posts featuring CancerWorld.

PATINA trial: Phase III Trial of Palbociclib, Anti-HER2 Therapy, and Endocrine Therapy vs. Anti-HER2 Therapy and Endocrine Therapy in HR+/HER2+ Metastatic Breast Cancer

Paolo Tarantino: Cure is a word we rarely use in metastatic breast cancer

Breast Cancer cancer metastatic breast cancer OncoDaily Oncology Paolo Tarantino
Special Coverage
Insight
Jul 28, 2025, 10:17
Real-World Insights Into Pulmonary Sarcomatoid Carcinoma, Shared by Laura Alder and Tejas Patil
Blog
Jul 28, 2025, 10:00
Miriam Mutebi: What Does AI Have to Do with African Women Facing Breast Cancer?
Insight
Jul 28, 2025, 09:59
Dr. Daniel Heng – Breakthrough Research Award: Yvonne Awards 2025
Blog
Jul 28, 2025, 09:54
Scientific Progress Drives Development of Therapies Targeting Disease at the Cellular Source - Servier
Blog
Jul 28, 2025, 09:52
Thor Halfdanarson: Bassam Sonbol on Emerging Targets in Gastroesophageal Cancers at MD Education Meeting
Dialogues
Jul 28, 2025, 09:49
Empowering Oncologists: Evolving role of AI in Oncology
Dialogues
Jul 28, 2025, 09:47
How Can We Better Support Cancer Patients? Lidia Schapira Shares Insights | MASCC 2025
Science
Jul 28, 2025, 09:45
Yan Leyfman: When is Risk-Reducing Mastectomy (RRM) Cost-Effective?
Blog
Jul 28, 2025, 09:36
How Reirradiation is Becoming a Key Strategy in Recurrent Glioma Care - ESTRO
Science
Jul 28, 2025, 09:34
Myeloma Paper of the Day, July 28th, Suggested by Robert Orlowski
Blog
Jul 28, 2025, 09:27
Hannatu Ayuba: The Survivor Stories Inspire Action for Improvements and Changes in Policy
Blog
Jul 28, 2025, 09:13
Pim van der Harst: Shaping the Future of Cardio-Oncology Education